Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 327-338

  Nakamura, Tadakatsu ^a   Kubota, Tomoko ^a   Iwakaji, Atsushi ^a   Imada, Masayoshi ^a   Kapás, Margit ^b   Morio, Yasunori ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b GEDEON RICHTER LTD   (Hungary)

Author keywords

Cariprazine; Desmethyl cariprazine; Didesmethyl cariprazine; Pharmacokinetics; Schizophrenia

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARIPRAZINE; CREATINE KINASE; DESMETHYL CARIPRAZINE; DIDESMETHYL CARIPRAZINE; PROLACTIN; UNCLASSIFIED DRUG; DESMETHYLCARIPRAZINE; DIDESMETHYLCARIPRAZINE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

ADULT; AKATHISIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CATARACT; CHILL; CLINICAL ARTICLE; COLD SWEAT; CONSTIPATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DENTAL CARIES; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTRITIS; GASTROENTERITIS; HUMAN; HYPERKERATOSIS; LEUKOCYTE COUNT; LIMB PAIN; LIVER FUNCTION TEST; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINOPHARYNGITIS; SCHIZOPHRENIA; SOMNOLENCE; STEADY STATE; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CLINICAL TRIAL; DOSE RESPONSE; HALF LIFE TIME; MIDDLE AGED;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84955079652     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S95100     Document Type: Article

References (32)

1. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr Res. 2009;110(1–3):1–23.
2. Haller CS, Padmanabhan JL, Lizano P, Torous J, Keshavan M. Recent advances in understanding schizophrenia. F1000Prime Rep. 2014;6:57.
3. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010;122(1–3):1–23.
4. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1081–1090.
5. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223.
6. Gross G, Wicke K, Drescher KU. Dopamine D(3) receptor antagonism – still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(2):155–166.
7. Millan MJ, Gressier H, Brocco M. The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Eur J Pharmacol. 1997;321(3):R7–R9.
8. Gyertyán I, Sághy K, Laszy J, et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. Behavioural characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(5):529–539.
9. Millan MJ, Dekeyne A, Rivet JM, Dubuffet T, Lavielle G, Brocco M. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther. 2000;293(3):1063–1073.
10. Laszy J, Laszlovszky I, Gyertyán I. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berl). 2005;179(3):567–575.
11. Millan MJ, Di Cara B, Dekeyne A, et al. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem. 2007;100(4):1047–1061.
12. Leggio GM, Micale V, Drago F. Increased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST). Eur Neuropsychopharmacol. 2008;18(4):271–277.
13. Gross G, Drescher K. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol. 2012;(213):167–210.
14. Kiss B, Laszlovszky I, Horváth A, et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. Neurochemical characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(5):515–528.
15. Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today. 2005;10(13):917–925.
16. Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333(1):328–340.
17. Kiss B, Horti F, Bobok A. Cariprazine, a D3/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics. Schizophr Res. 2012;136(Suppl 1):S190.
18. Papp M, Gruca P, Lason-Tyburkiewicz M, Adham N, Kiss B, Gyertyán I. Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav Pharmacol. 2014;25(5–6):567–574.
19. Zimnisky R, Chang G, Gyertyán I, Kiss B, Adham N, Schmauss C. Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl). 2013;226(1):91–100.
20. Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2–3):450–457.
21. Kane JM, Zukin S, Wang Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015;35(4):367–373.
22. Durgam S, Cutler AJ, Lu K, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase III randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. In press.
23. Debelle M, Németh G, Szalai E, et al. Cariprazine as monotherapy for the treatment of schizophrenia patients with predominant negative symptoms: a double-blind, active controlled trial. Eur Neuropsychopharmacol. 2015;25(Suppl 2):S510.
24. Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013;9(2):193–206.
25. Mészáros GP, Kapás M, Borsos M, et al. Pharmacokinetics of RGH-188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in healthy subjects. Eur Neuropsychopharmacol. 2007;17(Suppl 4):S451–S452.
26. Ereshefsky L, Andor G, Gage A, et al. Phase I study of RGH-188 in schizophrenic patients. Poster presented at: the 161st Annual Meeting of the American Psychiatric Association; May 3–8; 2008; Washington, DC.
27. Mészáros GP, Ágai-Csongor E, Kapás M. Sensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urine. J Pharm Biomed Anal. 2008;48(2):388–397.
28. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
29. Guy W, editor. The clinician global severity and impression scales. In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976:218–222. DHEW Publication No 76-338.
30. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 2005;28(3):191–208.
31. Weber NS, Cowan DN, Millikan AM, Niebuhr DW. Psychiatric and general medical conditions comorbid with schizophrenia in the National Hospital Discharge Survey. Psychiatr Serv. 2009;60(8):1059–1067.
32. Durgam S, Earley W, Li R, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2015;25(Suppl 2):S512–S513.